Viking Explores Metabolic Disorders With Drugs Licensed From Ligand
This article was originally published in The Pink Sheet Daily
Executive Summary
The start-up is launching with a focus on metabolic and endocrine disorders through a deal with Ligand that will flesh out its pipeline and give it a major shareholder.